Subscribe To
BGNE / What Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'
BGNE News
By Seeking Alpha
September 24, 2023
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a more_horizontal
By Reuters
September 19, 2023
BeiGene regains rights for cancer drug after Novartis deal termination
BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis. more_horizontal
By MarketBeat
July 28, 2023
7 Best Cancer Stocks to Invest in Now
One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. more_horizontal
By Zacks Investment Research
April 10, 2023
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. more_horizontal
By The Motley Fool
April 6, 2023
Why BeiGene Stock Jumped Thursday
BeiGene's shares are up more than 8% this year. The company has more than 60 clinical programs. more_horizontal
By Forbes
March 22, 2023
BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024
BeiGene aims to tap the area's life sciences talent pool. more_horizontal
By Zacks Investment Research
February 28, 2023
Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)
BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. more_horizontal
By Zacks Investment Research
February 27, 2023
Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal